Doorka laga yaabo inay joojiyaan daawada PARP ee daaweynta kansarka naasaha Daawooyin dhowr ah oo loo yaqaan 'PARP inhibitors' ayaa dhawaan lagu soo bartay daaweynta kansarka naasaha. Maxay daaweyntan daaweyntu ka qabanaysaa, iyo maxay noqon kartaa doorka ay ka ciyaaraan maaraynta dadka qaba kansarka naasaha?
Ku saabsan Hagaajinta Daaweynta iyo DNA-ga
PARP waa erayga gaaban ee poly (ADP-ribose) polymerase.
PARP waa borotiin oo leh doorarro badan oo ku saabsan hababka gacanta, ugu badnaan tan oo ah dayactirka DNA iyo barnaamijka dhimashada unugyada (apoptosis). Unugyada caafimaadku waxay isticmaali karaan PARP si ay u dayacaan oo ay u noolaadaan noloshooda caadi ah. Laakiin unugyada kansarka ayaa sidoo kale isticmaali kara PARP si loo hagaajiyo waxyeellada DNA, sidaas awgeedna ay kor u qaadaan kobaca aan la xakamayn. Kansarrada noocan oo kale ah waxay u adkeysan karaan daaweynta. Waxaa jira dhowr borotiin oo kala duwan, waxayna mid waliba leeyihiin doorkooda shaqadooda gudaha gudaha unugyada.
Ka hortaga PARP iyo Daaweynta Kansarka Naasaha
Ka-hortag PARP waa daawo ka dhigaysa borotiinka PARP-ga in ay fuliyaan doorkooda hagaajinta unugyada kansarka ee waxyeelloobay. Chemotherapy iyo shucaaca shaqada adoo jabinaya DNA-da unugyada si aysan u dhalin karin. Qaar ka mid ah unugyada kansarka ayaa isticmaala unugyada PARP si loo dayactiro waxyeelladooda DNA iyo ka soo kabashada weerarka daaweynta kansarka. Dhawr tijaabo caafimaad ayaa la sameeyaa si loo arko haddii daawooyinka PARP, oo lagu daro daaweynta kansarka kale, waxay xakameyn kartaa borotiinka PARP ee unugyada kansarka burburay.
Saamaynta Kansarka Kansarka Naasaha
Haddii daaweenta PARP in lagu daro daweynta kemotherabi ee kansarka naasaha, cilmi-baarayaasha ayaa rajaynaya unugyada kansarka ee ka soo horjeeda daawooyinka ladagaallanka ah inay u noqdaan kuwo u nugul waxyeellada DNA ee dhimashada. Xaaladaha qaarkood, daaweeye PARP ayaa loo isticmaali karaa kali ahaan, halkii ay ku xiran lahaayeen kiimikada iyo shucaaca.
Xitaa wanagsanaanta wargeyska ayaa ah in carqaladaha PARP aysan u muuqan inay saameynayaan unugyada caadiga ah, kuwa aan kansarka lahayn. Taas macnaheedu waa saameyno yar oo ka iman karta bukaanada iyo soo kabashada degdegga ah ee daaweynta.
Hope for Kansarka Naasaha
Ka-hortagayaasha PARP waxay si gaar ah u caawin karaan bukaanka qaba kansarka naasaha. Dadka qaba BRCA1 iyo isbeddellada hidda- wadnaha ee BRCA2 waxay ku jiraan khatar aad u sareeya oo ku dhaca kansarka naasaha. Noocyo caafimaad qaba BRCA waxay soo saaraan borootiinka oo xakameyn kara abuurista burooyinka ( waxaa loo yaqaan 'genes suppressor genes' ), laakiin unugyada BRCA-ga waxay awood u leeyihiin inay sameeyaan borotiinkan la dagaallanka unugyada kansarka. Ka-hortagayaasha PARP waxay ka faa'iideysan karaan daciifnimada ay ka mid tahay unugyada kansarka oo leh mutacal BRCA. Mid ka mid ah isticmaalka suurtogalka ah ee joojiya daawada PARP waxay noqon kartaa ka hortagga kansarka naasaha ee la iska dhaxlo . Laga yaabe inhibitorayaasha PARP inay noqdaan daaweyn ka hortag ah oo loogu talagalay haweenka khatarta sare leh waxayna samayn karaan ficil-celin-celin macquul ah.
Ku dhiirigelinta wararka ku saabsan Kansarka Naasaha ee Triple-Negative
Tijaabooyin dhowr ah oo daaweyn ah ee daawooyinka PARP waxay heleen qaar ka mid ah faa'iidooyinka daaweynta ee lagu daray isku-darka PSP inhibitorka daaweynta kale ee loogu talagalay kansarka naasaha ee saddex geesoodka ah . Daraasooyinkan, carqaladaha PARP waxay si fiican u dulqaadanayeen. Waqtigan xaadirka ah kaliya daaweynta loogu talagalay daaweynta loogu talagalay kansarka naas-nuujinta ayaa ah bevacizumab, laakiin daawadani maahan wax faa'iido gaar ah oo loogu talagalay dadka qaba kansarka naasaha saddex-geesoodka ah.
Isticmaalka Kale ee Loogu Talagalay Dhibaatooyinka Baarista
Daroogooyinka la soo saaray daawada PARP waxaa lagu baari karaa dhowr nooc oo kansar ah: naasaha iyo ugxan-yarta, uterine, maskaxda, iyo xayawaan-xayawaan. Sannadka 2015, daawada PARP inhibitor waxaa loo ansixiyey daaweynta kansarka ugxan-badan.
Muhiimadda Muhiimka ah ee Waxyeelayaasha Baarista ee PARP
Ku darida daawada culeeyska ah ee PARP-ga ee hadda ku jirta hubka ka soo horjeeda kansarka naasuhu waxay u muuqdaan kuwo aad u ballan qaadaya. Ka-hortagayaasha PARP waxay kordhiyaan wax-ku-oolnimada kiimiko-daweynta ee ka hortagga kansarka naasaha iyo sedexda-naasood ee naasaha, taasoo dhici karta iyada oo aan lagu darin waxyeellooyin badan oo culus. Daroogooyinkaasi waxay u muuqdaan inay kor u qaadayaan tayada nolosha iyo sidoo kale sii waarida bukaannada.
La dagaallanka kansarka naasaha heerka heerka DNA waxay u egtahay mawjada mustaqbalka.
> Ilo:
> Boerner, J. et al. Calaamadaha Protein Noocyada Xakamaynta Dufanka DNA-da waxay xoojinaysaa jawaab-celinta Topoisomerase iyo Ka-hortagayaasha PARP ee Kansarka Naas-nuujinta ee Triple-negative. Hal jibbaar . 2015. 10 (3: e0119614.
> Comen, E., iyo M. Robson. Poly (ADP-ribose) Polymerase Inhibitors ee Kansarka Naasaha ee Triple-negative. Cudurka Kansarka . 2010. 16 (1): 48-52.
> Dizdar, O., Arslan, C., iyo K. Altundaq. Horumarinta Ka-hortagga Maskaxda ee Daaweynta Kansarka Naasaha. Fikradda Khibradda leh ee Faragotherabi . 2015. 16 (18): 2751-8.
> Garber, J., iyo L. Livraghi. Ka-hortagga PARP ee Maareynta Kansarka Naasaha: Xogta Socda iyo mustaqbalka mustaqbalka. BMC Medicine . 2015. 13: 188.
> Hiller, D., iyo Q. Chu. Xaaladda Xaadirka ah ee Poly (ADP-Ribose) Polymerase Inhibitors sida Wareegyo Daweyneed oo Cusub oo loogu talagalay Kansarka Naas-nuujinta ee Triple-Negative. Wargeyska Caalamiga ah ee Kansarka Naasaha . 2012. 2012: 829315.
> Lee, J. et al. Wajiga I / Ib Daraasadda Olaparib iyo Carboplatin ee BRCA1 ama BRCA2 Xuddun-ku-xirnaanshaha Kansarka Naas-nuujinta ama Naas-nuujinta Qiimaynta Biomarker. Wargeyska Machadka Kansarka Qaranka . 2014. 106 (6): dju089.
> O'Shaughnessy, J. et al. Inäterb Plus Chemotherapy oo ku jira daaweynta kansarka naasaha ee Triple-negative. Wargeyska New England Journal of Medicine . 2011. 364 (3): 205-14.
> O'Shaughnessy, J. et al. Wargeyska Oncology . 2014. 32 (34): 3840-7.
> O'Sullivan, C., Chen, A., iyo S. Kummar. Bixinta Ballan-qaadka: Cadaadiska Dabaysha ee Polymerase PolyRepose Polymerase waa loola dhaqmey sidii loola dhaqmey lidka faraha. Fikradaha Hadda ee Onkoloji . 2015. 27 (6): 475-81.
> Rios, J., iyo S. Puhalla. PARP Isugeynta Kansarka Naasaha: BRCA iyo Beyond. Oncology (Beerta Williston) . 2011. 25 (11): 1014-25.
> van der Noll, R. et al. Waxqabadka Ammaanka Waqti-dheer iyo Ka-hor-imaadiyaha Olofarib Monotherapy Kaddib Isku-darka Carboplatin iyo Paclitaxel ee bukaan-jiifka qaba Bukaanka Hore, Kansarka ama Fallopian Tube. British Journal of Cancer . 2015. 113 (3): 396-402.